Cycle on Jul 15, 2026

I will start by listing the topic's open threads to see if there are any specific questions, watches, or priorities already established. I will then perform web searches focused on recent, high-impact science and health updates since our last check in late June / early July 2026.

I will perform a web search to check for updates on some of the key immediate events and regulatory decisions in late July 2026, specifically looking at the Capricor Cellular, Tissue, and Gene Therapies Advisory Committee meeting on deramiocel, the Replimune RP1 advisory committee meeting/PDUFA, and other major drug approvals or health breakthroughs.

I see high-stakes news regarding Capricor's deramiocel (CAP-1002) for DMD cardiomyopathy. There is a legal fight over its commercialization path, and a former Capricor executive is being discussed for an FDA gene therapy role. Let's fetch the Pharmavoice article (`https://www.pharmavoice.com/news/Moderna-Takeda-Capricor-drug-approvals-q3/824993/`) and search for information about the Capricor lawsuit and the Replimune RP1 AdCom/PDUFA.

I will search for the specific details of Capricor's lawsuit against Nippon Shinyaku/NS Pharma using a more targeted search query. I also need to check on Replimune's RP1 advisory committee meeting status.

I will fetch the Biostockinfo scan or the stocktwits article to get details about the lawsuit, and search for the Replimune RP1 FDA advisory committee meeting status. Let's fetch the Biostockinfo link first: `https://www.biostockinfo.com/biotech-catalyst-ai-scanner-july-wk3/`.

I will search specifically for "Replimune" "RP1" "advisory committee" or "FDA" to see if there is any update on the Replimune PDUFA (scheduled for August 2, 2026) or the advisory committee meeting.

Let's search for "Saol Therapeutics" and their FDA resubmission, as well as fetch the Biospace article `https://www.biospace.com/fda/saol-boards-fdas-resubmission-boat-armed-with-new-survival-data` — this seems highly relevant to the "Post-Makary FDA Pivot" and how companies are resubmitting drugs that were recently rejected. Let's do that.

This is a fantastic update on the post-Makary FDA pivot, highlighting Saol Therapeutics' resubmission of SL1009 (DCA) on June 30, 2026, with an expected filing acceptance/PDUFA date setting prior to July 30, 2026. This ties directly into our existing note `fda-regulatory-pivot-advisory-committees-capricor-replimune`. I will update that note accordingly. Let's do a search on Capricor's lawsuit against Nippon Shinyaku / NS Pharma to get the details of the pricing dispute, because that directly impacts the commercialization of deramiocel, which is facing an upcoming FDA advisory committee meeting on July 29, 2026.

I will fetch `https://stocktwits.com/news-articles/markets/equity/capr-stock-sinks-deramiocel-lawsuit-ahead-of-fda-review/cZX2RmqReQM` to see the details of the Capricor vs. Nippon Shinyaku / NS Pharma lawsuit. This is a crucial piece of news directly updating the Capricor/deramiocel story.

Ah, Stocktwits returned a 403. Let's search for "Capricor" "Nippon" or "NS Pharma" lawsuit on other news sites or press release sites (like GlobeNewswire, PR Newswire, etc.) to get a clean, fetchable source.

Let's broaden the search query without the site filters to find a news article or press release about Capricor's lawsuit against Nippon Shinyaku. I will search for `Capricor lawsuit Nippon Shinyaku July 2026` or `Capricor sues NS Pharma`.

Let's search for `Capricor "rescission" "NS Pharma" OR "Nippon Shinyaku"` or `"pricing flaw"` to see if we can get a readable SEC filing or another biotech news source detailing the lawsuit. SEC filings (like 8-K) are great. Let's do a search on SEC filings or biotech publications.

Let's try a search for the SEC filings of Capricor Therapeutics (CAPR) directly using the query `Capricor "8-K" "Nippon Shinyaku"` or `"rescission"` or `"pricing"` in July 2026. This will give us the direct filing details.

Let's search for Capricor's 8-K filings on the SEC EDGAR system or search engines specifically looking for filings in July 2026 that mention "Nippon" or "NS Pharma" or "rescission" or "lawsuit" to find the exact date and details. Let's run a search for: `Capricor "Item 8.01" OR "Item 1.01" "Nippon" OR "NS Pharma" July 2026`.

Ah, the search budget is spent. No problem, we have plenty of high-quality evidence. Let's review the findings we have: 1. **The Post-Makary FDA Pivot / Saol Therapeutics DCA Resubmission**: - Saol Therapeutics resubmitted its NDA for SL1009 (DCA) for pyruvate dehydrogenase complex deficiency (PDCD) on June 30, 2026. This comes after an initial rejection in September 2025 under former FDA Commissioner Marty Makary. - The company's resubmission includes additional survival data (36 natural history–matched pairs, demonstrating a 91% reduction in the risk of death with SL1009). The FDA is expected to set a target action date before July 30, 2026. - This fits perfectly into the existing note `fda-regulatory-pivot-advisory-committees-capricor-replimune` (The Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees). I will update this note to include Saol Therapeutics' resubmission alongside Capricor, Replimune, uniQure, and REGENXBIO. 2. **Capricor's Deramiocel Legal Battle with NS Pharma**: - Capricor Therapeutics has filed a lawsuit (a rescission filing) against its U.S. commercialization and distribution partner, Nippon Shinyaku (and its U.S. subsidiary NS Pharma). - Capricor alleges that NS Pharma failed to prepare for the commercial rollout of deramiocel and refused to resolve critical pricing flaws within their commercialization and distribution agreement. Capricor seeks to rescind the U.S. distribution deal, claiming the pricing flaw would block insured patient access to the therapy. - Because of this legal action, analysts (e.g., Cantor Fitzgerald) have noted the removal of the expected $80 million milestone in Q4 2026 and a potential delay in the modeled U.S. launch of deramiocel to 2027. - This occurs just ahead of the high-stakes FDA advisory committee meeting scheduled for July 29, 2026, and the PDUFA target action date of August 22, 2026. - We should write a note on this under a durable slug like `capricor-deramiocel-ns-pharma-dispute` or update the existing `fda-regulatory-pivot-advisory-committees-capricor-replimune` note. However, a legal dispute over commercialization rights is a distinct theme/subject tracking a major corporate development. I will create a new note with slug `capricor-deramiocel-ns-pharma-dispute` or update the existing one if it makes sense. Wait, the guidelines say: "For each distinct theme or story worth persisting, call write_note — ONE note per theme, never a combined write-up." The legal dispute is a highly distinct corporate/commercial theme, so I will write a new note for it: `capricor-deramiocel-ns-pharma-dispute`. Let's look at the existing note title and structure from our semantic search: - `fda-regulatory-pivot-advisory-committees-capricor-replimune` (The Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees) I will first update `fda-regulatory-pivot-advisory-committees-capricor-replimune` to include Saol Therapeutics' resubmission of SL1009 (DCA) and the broader context of the FDA's newfound flexibility. I will then write a new note `capricor-deramiocel-ns-pharma-dispute` to document the legal fight over deramiocel's commercial rollout. Let's read the existing note `fda-regulatory-pivot-advisory-committees-capricor-replimune` first using `read_notes` to see what is already there so we can update it seamlessly.

I need to fetch the full list of notes or search specifically for the slug `fda-regulatory-pivot-advisory-committees-capricor-replimune` to read its content. Let's do a search or fetch the note. Since we don't have a direct "read note by slug" tool, I can call `read_notes` with a larger limit or search. Let's increase the limit to 50 to find the note.

I will now write the updated finding for `fda-regulatory-pivot-advisory-committees-capricor-replimune` to include Saol Therapeutics' resubmission on June 30, 2026. After that, I will write the new finding for `capricor-deramiocel-ns-pharma-dispute` regarding Capricor's lawsuit against Nippon Shinyaku / NS Pharma. Then, I will resolve the corresponding threads and watches, and finish the cycle. Let's do this step-by-step.

Now I will write the new finding for `capricor-deramiocel-ns-pharma-dispute` regarding Capricor's lawsuit against Nippon Shinyaku / NS Pharma over the commercialization of deramiocel.

I will now check if any of the open threads/watches can be resolved. - Thread ID `019f061f-f34a-7079-a276-d216329928b2` is a watch for the FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy, which is scheduled for July 29, 2026. This date has not yet arrived (it is currently July 15, 2026), so this watch is ongoing and does not fire yet. - Saol Therapeutics resubmitted its NDA on June 30, 2026, and expects a target action date before July 30, 2026. This is a newly surfaced development, but there is no explicit open thread or watch registered for Saol's resubmission (only general ones). Let's register a new watch to monitor Saol's upcoming FDA decision or filing acceptance, or update existing watches if applicable. The existing watch `019f1ab8-f9db-7f35-b537-f4db6a56efeb` is for the "Expedited-IND Pilot Program". Let's see if we should record a watch for Saol's NDA filing acceptance / PDUFA date. Yes, it's a great forward-looking trigger. Let's record a watch for Saol's NDA target action date assignment.

Now, I will finish the research cycle. I have updated the core living findings with very specific evidence, quotes, and links, and registered a new watch for Saol's SL1009. No other threads or watches have fired yet as of July 15, 2026. Let's call `finish_cycle`.

I have successfully completed the research cycle. Here is a summary of the outcomes: 1. **The Post-Makary FDA Pivot (`fda-regulatory-pivot-advisory-committees-capricor-replimune`)**: - Updated the living note to include **Saol Therapeutics'** resubmission of its NDA for **SL1009 (DCA)** on June 30, 2026, for pyruvate dehydrogenase complex deficiency (PDCD). - Documented how Saol successfully negotiated a path forward with the FDA based on additional survival analyses (showing a 91% reduction in the risk of death) rather than a costly and lengthy new Phase 3 trial, representing yet another concrete example of the agency's post-Makary operational flexibility. 2. **Capricor's Deramiocel Legal Dispute (`capricor-deramiocel-ns-pharma-dispute`)**: - Formulated a new note tracking the newly erupted legal battle between **Capricor Therapeutics** and its U.S. commercialization partner **Nippon Shinyaku / NS Pharma**. - Capricor is suing to rescind their U.S. distribution deal over "pricing flaws" that it argues would block patient access. This dispute has led analysts to push back modeled U.S. launch timelines to 2027, occurring just weeks before Capricor's critical July 29, 2026, FDA Advisory Committee meeting and August 22, 2026, PDUFA date. 3. **Forward-Looking Watches**: - Registered a new one-shot watch to monitor the FDA's decision to accept Saol's resubmitted NDA and assign a PDUFA target action date (expected before July 30, 2026).